Login / Signup

Neratinib in HER2-Positive Breast Cancer Patients.

Rutugandha ParanjpeDima BasatnehGabriel TaoCarmine De AngelisSobia NoormohammedEkim EkinciSusan AbughoshRomi GhoseMeghana V Trivedi
Published in: The Annals of pharmacotherapy (2019)
Neratinib significantly improves treatment outcomes and has manageable toxicity in stage I to III HER2+ BC patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • oxidative stress
  • positive breast cancer
  • oxide nanoparticles